JP2020503013A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020503013A5 JP2020503013A5 JP2019531740A JP2019531740A JP2020503013A5 JP 2020503013 A5 JP2020503013 A5 JP 2020503013A5 JP 2019531740 A JP2019531740 A JP 2019531740A JP 2019531740 A JP2019531740 A JP 2019531740A JP 2020503013 A5 JP2020503013 A5 JP 2020503013A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- seq
- composition according
- antibody
- adm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023009286A JP2023052614A (ja) | 2016-12-16 | 2023-01-25 | うっ血の処置と治療を必要とする患者でその処置と治療に使用するための抗アドレノメデュリン（ＡＤＭ）抗体、または抗ＡＤＭ抗体フラグメント、または抗ＡＤＭ非Ｉｇ足場 |
| JP2024143320A JP2024170454A (ja) | 2016-12-16 | 2024-08-23 | うっ血の処置と治療を必要とする患者でその処置と治療に使用するための抗アドレノメデュリン（ＡＤＭ）抗体、または抗ＡＤＭ抗体フラグメント、または抗ＡＤＭ非Ｉｇ足場 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16204847.4 | 2016-12-16 | ||
| EP16204847 | 2016-12-16 | ||
| EP16206305.1A EP3339324A1 (en) | 2016-12-22 | 2016-12-22 | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof |
| EP16206305.1 | 2016-12-22 | ||
| EP17197176.5 | 2017-10-18 | ||
| EP17197176 | 2017-10-18 | ||
| PCT/EP2017/083311 WO2018109228A1 (en) | 2016-12-16 | 2017-12-18 | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023009286A Division JP2023052614A (ja) | 2016-12-16 | 2023-01-25 | うっ血の処置と治療を必要とする患者でその処置と治療に使用するための抗アドレノメデュリン（ＡＤＭ）抗体、または抗ＡＤＭ抗体フラグメント、または抗ＡＤＭ非Ｉｇ足場 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020503013A JP2020503013A (ja) | 2020-01-30 |
| JP2020503013A5 true JP2020503013A5 (cg-RX-API-DMAC7.html) | 2021-02-04 |
| JP7727371B2 JP7727371B2 (ja) | 2025-08-21 |
Family
ID=61148166
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019531740A Active JP7727371B2 (ja) | 2016-12-16 | 2017-12-18 | うっ血の処置と治療を必要とする患者でその処置と治療に使用するための抗アドレノメデュリン（ＡＤＭ）抗体、または抗ＡＤＭ抗体フラグメント、または抗ＡＤＭ非Ｉｇ足場 |
| JP2023009286A Pending JP2023052614A (ja) | 2016-12-16 | 2023-01-25 | うっ血の処置と治療を必要とする患者でその処置と治療に使用するための抗アドレノメデュリン（ＡＤＭ）抗体、または抗ＡＤＭ抗体フラグメント、または抗ＡＤＭ非Ｉｇ足場 |
| JP2024143320A Pending JP2024170454A (ja) | 2016-12-16 | 2024-08-23 | うっ血の処置と治療を必要とする患者でその処置と治療に使用するための抗アドレノメデュリン（ＡＤＭ）抗体、または抗ＡＤＭ抗体フラグメント、または抗ＡＤＭ非Ｉｇ足場 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023009286A Pending JP2023052614A (ja) | 2016-12-16 | 2023-01-25 | うっ血の処置と治療を必要とする患者でその処置と治療に使用するための抗アドレノメデュリン（ＡＤＭ）抗体、または抗ＡＤＭ抗体フラグメント、または抗ＡＤＭ非Ｉｇ足場 |
| JP2024143320A Pending JP2024170454A (ja) | 2016-12-16 | 2024-08-23 | うっ血の処置と治療を必要とする患者でその処置と治療に使用するための抗アドレノメデュリン（ＡＤＭ）抗体、または抗ＡＤＭ抗体フラグメント、または抗ＡＤＭ非Ｉｇ足場 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20200299372A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3555130A1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP7727371B2 (cg-RX-API-DMAC7.html) |
| KR (3) | KR20250084231A (cg-RX-API-DMAC7.html) |
| CN (2) | CN110167962B (cg-RX-API-DMAC7.html) |
| AU (2) | AU2017375049B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112019011713A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3046850A1 (cg-RX-API-DMAC7.html) |
| IL (2) | IL322765A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2019007107A (cg-RX-API-DMAC7.html) |
| MY (1) | MY208219A (cg-RX-API-DMAC7.html) |
| RU (2) | RU2762059C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018109228A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3854414A1 (en) * | 2017-09-25 | 2021-07-28 | AdrenoMed AG | Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness |
| EP3871689A1 (en) * | 2020-02-26 | 2021-09-01 | sphingotec GmbH | Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c |
| IL295728A (en) * | 2020-02-27 | 2022-10-01 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock |
| AU2021238591A1 (en) * | 2020-03-16 | 2022-11-17 | Adrenomed Ag | Pro-Adrenomedullin or fragment thereof in patients infected with Corona virus and treatments with binder against adrenomedullin |
| WO2023175035A1 (en) | 2022-03-15 | 2023-09-21 | Adrenomed Ag | Stable aqueous formulation of an anti-adrenomedullin (adm) antibody or anti-adm antibody fragment |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| AU634716B2 (en) | 1988-08-01 | 1993-03-04 | Ciba Corning Diagnostics Corp. | Method for detection of an analyte using acridinium esters and liposomes |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| ATE139258T1 (de) | 1990-01-12 | 1996-06-15 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| EP0585287B1 (en) | 1990-07-10 | 1999-10-13 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| EP0746609A4 (en) | 1991-12-17 | 1997-12-17 | Genpharm Int | NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES |
| JP2774769B2 (ja) | 1993-04-26 | 1998-07-09 | 賢治 寒川 | アドレノメデュリン |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| WO2003020746A1 (en) | 2001-08-30 | 2003-03-13 | Biorexis Pharmaceutical Corporation | Modified transferrin fusion proteins |
| EP2298278B1 (en) | 2002-06-07 | 2015-11-11 | Dyax Corp. | Prevention and reduction of blood loss and inflammatory response |
| DE10316583A1 (de) | 2003-04-10 | 2004-10-28 | B.R.A.H.M.S Aktiengesellschaft | Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung |
| US20070082363A1 (en) | 2003-04-25 | 2007-04-12 | Lydie Bougueleret | Secreted polypeptide species reduced cardiovascular disorders |
| EP1675878A2 (en) | 2003-10-24 | 2006-07-05 | Avidia, Inc. | Ldl receptor class a and egf domain monomers and multimers |
| US20100028995A1 (en) | 2004-02-23 | 2010-02-04 | Anaphore, Inc. | Tetranectin Trimerizing Polypeptides |
| WO2006027147A2 (en) | 2004-09-09 | 2006-03-16 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with adrenomedullin receptor (amdr) |
| EP1793847A2 (en) | 2004-09-21 | 2007-06-13 | NascaCell IP GmbH | Use of microproteins as tryptase inhibitors |
| EP2231860B1 (en) | 2007-12-19 | 2011-10-05 | Affibody AB | Polypeptide derived from protein a and able to bind pdgf |
| AU2009266414A1 (en) * | 2008-07-01 | 2010-01-07 | Arana Therepeutics (Vic) Pty Ltd | Anti-PAMP therapeutic antibodies |
| MX359570B (es) | 2008-11-03 | 2018-10-01 | Molecular Partners Ag | Proteinas de union que inhiben la interaccion en el receptor de vegf-a. |
| US9376477B2 (en) | 2009-08-27 | 2016-06-28 | Covagen Ag | IL-17 binding compounds and medical uses thereof |
| WO2011073214A2 (en) | 2009-12-14 | 2011-06-23 | Scil Proteins Gmbh | A method for identifying hetero-multimeric modified ubiquitin proteins with binding capability to ligands |
| JP5902679B2 (ja) | 2010-06-08 | 2016-04-13 | ピエリス アーゲーＰｉｅｒｉｓ Ａｇ | ＩＬ−４Ｒαに結合する涙液リポカリンムテイン |
| EP2583103B1 (en) * | 2010-06-18 | 2016-04-20 | B.R.A.H.M.S GmbH | Biomarkers for the prediction of incident cancer |
| AU2012338733B2 (en) * | 2011-11-16 | 2017-08-24 | Adrenomed Ag | Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation |
| AU2012338732B2 (en) * | 2011-11-16 | 2017-07-20 | Adrenomed Ag | Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment or an anti-ADM non-Ig scaffold for use in therapy |
| NZ624873A (en) * | 2011-11-16 | 2016-07-29 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition |
| PL2594587T3 (pl) | 2011-11-16 | 2014-11-28 | Adrenomed Ag | Przeciwciało przeciwko adrenomedulinie (ADM) lub fragment przeciwciała anty-ADM lub szkielet białkowy niestanowiący Ig anty-ADM do zmniejszenia ryzyka śmierci u pacjenta cierpiącego na chorobę przewlekłą lub ostrą lub stan ostry |
| EP2780371B1 (en) * | 2011-11-16 | 2018-10-24 | AdrenoMed AG | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for regulating the fluid balance in a patient having a chronic or acute disease |
| MY192113A (en) * | 2011-11-16 | 2022-07-28 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment of anti-adm non-ig protein scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition |
-
2017
- 2017-12-18 KR KR1020257017044A patent/KR20250084231A/ko active Pending
- 2017-12-18 BR BR112019011713-0A patent/BR112019011713A2/pt unknown
- 2017-12-18 MX MX2019007107A patent/MX2019007107A/es unknown
- 2017-12-18 RU RU2019122135A patent/RU2762059C2/ru active
- 2017-12-18 CN CN201780077335.5A patent/CN110167962B/zh active Active
- 2017-12-18 KR KR1020197020162A patent/KR20190120174A/ko not_active Ceased
- 2017-12-18 CN CN202410627213.0A patent/CN118767128A/zh active Pending
- 2017-12-18 JP JP2019531740A patent/JP7727371B2/ja active Active
- 2017-12-18 US US16/469,738 patent/US20200299372A1/en not_active Abandoned
- 2017-12-18 KR KR1020247006366A patent/KR20240033285A/ko not_active Ceased
- 2017-12-18 AU AU2017375049A patent/AU2017375049B2/en active Active
- 2017-12-18 MY MYPI2019003407A patent/MY208219A/en unknown
- 2017-12-18 RU RU2021135712A patent/RU2021135712A/ru unknown
- 2017-12-18 WO PCT/EP2017/083311 patent/WO2018109228A1/en not_active Ceased
- 2017-12-18 IL IL322765A patent/IL322765A/en unknown
- 2017-12-18 CA CA3046850A patent/CA3046850A1/en active Pending
- 2017-12-18 EP EP17837953.3A patent/EP3555130A1/en active Pending
-
2019
- 2019-06-12 IL IL267282A patent/IL267282A/en unknown
-
2021
- 2021-06-04 US US17/339,221 patent/US20220041703A1/en active Pending
-
2023
- 2023-01-25 JP JP2023009286A patent/JP2023052614A/ja active Pending
-
2024
- 2024-08-23 JP JP2024143320A patent/JP2024170454A/ja active Pending
-
2025
- 2025-04-29 AU AU2025202983A patent/AU2025202983A1/en active Pending